2179.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 03:07):

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China...

Stats
Today's Volume	31 000.00
Average Volume	9 842.00
Market Cap	4.38B
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-7.11
ATR14	HKD0 (0.00%)

Jiangsu Recbio Technology Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Jiangsu Recbio Technology Financials

Annual	2022
Revenue:	HKD5.33M
Gross Profit:	HKD5.33M (100.00 %)
EPS:	HKD-1.520

Q3	2023
Revenue:	HKD0
Gross Profit:	HKD0 (0.00 %)
EPS:	HKD0

Q2	2023
Revenue:	HKD2.30M
Gross Profit:	HKD2.30M (100.00 %)
EPS:	HKD-0.280

Q1	2023
Revenue:	HKD2.30M
Gross Profit:	HKD2.30M (100.00 %)
EPS:	HKD-0.280

Financial Reports:

No articles found.

Jiangsu Recbio Technology

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.